Abstract：OBJECTIVE: To evaluate the efficacy and safety of ambroxol in the prevention of respiratory distress syndrome (RDS) in preterm infants. METHODS: Electronic searches were performed in the Cochrane Library, PubMED, EMBASE, Chinese CBM, Chinese VIP Database, Chinese Wanfang Database and Chinese CNKI Database up to the year of 2009 for randomized controlled trials (RCT) on ambroxol for the prevention of RDS in preterm infants. The meeting articles related to the RCT were manually searched in Pediatrics and Pediatric Research. Meta analysis was performed for the results of homogeneous studies by the Cochrane Collaboration′s software RevMan 5.0.17. RESULTS: Six RCTs involving 823 preterm infants were included, and the quality assessment for the trials demonstrated 1 article as A class, 1 article as B class and 4 articles as C class. The Meta analysis showed that ambroxol administration significantly reduced the incidence of RDS (OR=0.24, 95%CI: 0.15 - 0.64, P＜0.01), bronchopulmonary dysplasis (BPD, OR=0.41, 95%CI: 0.23 - 0.75, P＜0.01), intraventricular hemorrhage (IVH, OR=0.39, 95%CI:0.24 - 0.64, P＜0.01), patent ductus arteriosus (PDA, OR=0.33, 95%CI: 0.17 - 0.67, P＜0.01) and pulmonary infection (OR=0.24, 95%CI:0.14 - 0.38, P＜0.01). No adverse events related to the ambroxol treatment were reported. CONCLUSIONS: The current evidence shows that early use of ambroxol can reduce the risk of RDS, BPD, IVH, PDA and pulmonary infection in preterm infants.［Chin J Contemp Pediatr, 2010, 12 (11):858-863］
ZHANG Zhi-Qun,HUANG Xian-Mei,LU Hui. Ambroxol for the prevention of respiratory distress syndrome in preterm infants: a Meta analysis[J]. CJCP, 2010, 12(11): 858-863.
［1］Miracle X, Di Renzo GC, Stark A, Fanaroff A, Carbonell-Estrany X, Saling E. Guideline for the use of antenatal corticosteroids for fetal maturation［J］.J Perinat Med, 2008, 36 (2):191-196.
［3］Henderson-Smart DJ, Wilkinson A, Raynes-Greenow CH. Mechanical ventilation for newborn infants with respiratory failure due to pulmonary disease［DB/OL］.Cochrane Database Syst Rev, 2002, (4):CD002770.
［4］Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants［DB/OL］.Cochrane Syst Rev, 2001, (2):CD00510.
［5］Disse BG, Ziegler HW. Pharmacodynamic mechanism and therapeutic activity of ambroxol in animal experiments［J］.Respiration, 1987, 51(Suppl 1):15-22.
［6］Allegra L, Bossi R, Braga P. Influence of surfactant on mucociliary transport［J］.Eur J Respir Dis, 1985, 67(Suppl 142):71-76.
［7］Robertson B. Pharmacological stimulation of surfactant secretion and surfactant replacement［J］. Eur J Respir Dis, 1985, 67(Suppl 142):63-70.
［8］Pfeifer S, Zissel G, Kienast K, Müller-Quernheim J. Reduction of cytokine release of blood and bronchoalveolar mononuclear cells by ambroxol［J］.Eur J Med Res, 1997, 2（3）:129-132.
［9］Weiser T, Wilson N. Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na+ channels by the secretolytic ambroxol［J］. Mol Pharmacol, 2002, 62 (3):433-438.
［10］Weiser T.Comparison of the effects of four Na+ channel analgesics on TTX-resistant Na+ currents in rat sensory neurons and recombinant［J］. Neurosci Lett, 2006, 395（3）:179-184.
［11］Fabbri L, Pauwels RA, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary updated 2003［J］.COPD, 2004, 1(1):105-141.
［12］Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary diseases: systematic review［J］.BMJ, 2001, 322（7297）:1271-1274.
［13］Malerba M,Ponticiello A, Radaeli A, Bensi G, Grassi V. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD.Double-blind, randomized, multicenter,placebo-controlled study［J］.Pulm Pharmacol Ther, 2004, 17（1）:27-34.
［14］Luerti M, Lazzarin A, Corbella E, Zavattini G. An alternative to steroids for prevention of respiratory distress syndrome (RDS): Multicenter controlled study to compare ambroxol and betamethasone［J］.J Perinat Med, 1987, 15（3）:227-238.
［15］Wauer RR, Schmalisch G, B-hme B, Arand J, Lehmann D. Randomized double blind trial of ambroxol for the treatment of respiratory distress syndrome［J］.Eur J Pediatr, 1992, 151（5）:357-363.
［16］Fegiz G.Prevention by ambroxol of bronchopulmonary complications after upper abdominal surgery: double-blind Italian multicenter clinical study versus placebo［J］.Lung, 1991, 169（1）:69-76.
［17］Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.17［updated Dec 2008］ ［DB/OL］.The Cochrane Collaboration, 2008.Available at www.cochranehandbook.org.
［23］Marini A, Franzetti M, Gios G, Flauto U, Arosio A, Maccabruni M, et al. Ambroxol in the treatment of idiopathic respiratory distress syndrome. An interim report on a controlled double-blind multicenter study versus placebo［J］.Respiration, 1987, 51（Suppl 1）:60-67.
［24］Wauer RR, Schmalisch G, Hammer H, Buttenberg S, Weigel H, Huth M.Ambroxol for prevention and treatment of hyaline membrane disease［J］.Eur Respir J Suppl, 1989, 3（1）:57-65.
［25］Wauer RR, Schmalisch G, Kurze D, Rachmann B, Grauel EL.The use of ambroxol (bromhexine metabolite VIII) in the prevention and treatment of hyaline membrane disease (HMD)［J］.EJOG, 1983, 15（4）:421-424.
